In its third major acquisition in the past six weeks, Gilead is buying a company that will add NaPi2b- and 5T4-targeting agents to its portfolio.

The firm submitted data from the ALKOVE-1 trial, in which neladalkib shrunk tumors in 31 percent of patients and showed promising activity against CNS lesions.

The trial is evaluating how the disclosure of polygenic risk scores for cardiovascular disease affects patients' outcomes.

Preclinical testing has suggested that AIR-001 increases functional AAT protein levels and could address the lung and liver manifestations of the disease.

A study found that in about 10 percent of patients, WGS picked up on clinically actionable information other panels missed.